Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Risk-based treatment of non-rhabdomyosarcoma soft-tissue sarcoma in children.

Martin-Broto J.

Lancet Oncol. 2019 Nov 27. pii: S1470-2045(19)30679-5. doi: 10.1016/S1470-2045(19)30679-5. [Epub ahead of print] No abstract available.

PMID:
31786123
2.

Which goals should we pursue in each line of treatment for advanced soft tissue sarcoma?

Martin-Broto J, Hindi N, Moura DS.

Future Oncol. 2019 Sep 10. doi: 10.2217/fon-2019-0490. [Epub ahead of print]

PMID:
31500464
3.

Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial.

Stacchiotti S, Ferrari S, Redondo A, Hindi N, Palmerini E, Vaz Salgado MA, Frezza AM, Casali PG, Gutierrez A, Lopez-Pousa A, Grignani G, Italiano A, LeCesne A, Dumont S, Blay JY, Penel N, Bernabeu D, de Alava E, Karanian M, Morosi C, Brich S, Dagrada GP, Vallacchi V, Castelli C, Brenca M, Racanelli D, Maestro R, Collini P, Cruz J, Martin-Broto J.

Lancet Oncol. 2019 Sep;20(9):1252-1262. doi: 10.1016/S1470-2045(19)30319-5. Epub 2019 Jul 19. Erratum in: Lancet Oncol. 2019 Oct;20(10):e559.

PMID:
31331701
4.

Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.

Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, Alcindor T, Ganjoo K, Martín-Broto J, Ryan CW, Thomas DM, Peterfy C, Healey JH, van de Sande M, Gelhorn HL, Shuster DE, Wang Q, Yver A, Hsu HH, Lin PS, Tong-Starksen S, Stacchiotti S, Wagner AJ; ENLIVEN investigators.

Lancet. 2019 Aug 10;394(10197):478-487. doi: 10.1016/S0140-6736(19)30764-0. Epub 2019 Jun 19.

PMID:
31229240
5.

Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups.

Gronchi A, Hindi N, Cruz J, Blay JY, Lopez-Pousa A, Italiano A, Alvarez R, Gutierrez A, Rincón I, Sangalli C, Pérez Aguiar JL, Romero J, Morosi C, Sunyach MP, Sanfilippo R, Romagosa C, Ranchere-Vince D, Dei Tos AP, Casali PG, Martin-Broto J.

EClinicalMedicine. 2019 Mar 11;9:35-43. doi: 10.1016/j.eclinm.2019.03.007. eCollection 2019 Mar.

6.

In Reply.

Martin-Broto J, Hindi N.

Oncologist. 2019 Jun;24(6):e401-e402. doi: 10.1634/theoncologist.2019-0052. Epub 2019 Mar 7. No abstract available.

PMID:
30846512
7.

Pazopanib in the treatment of advanced solitary fibrous tumour - Authors' reply.

Martin-Broto J, Moura DS, Hindi N.

Lancet Oncol. 2019 Mar;20(3):e128. doi: 10.1016/S1470-2045(19)30080-4. No abstract available.

PMID:
30842052
8.

Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.

Martin-Broto J, Stacchiotti S, Lopez-Pousa A, Redondo A, Bernabeu D, de Alava E, Casali PG, Italiano A, Gutierrez A, Moura DS, Peña-Chilet M, Diaz-Martin J, Biscuola M, Taron M, Collini P, Ranchere-Vince D, Garcia Del Muro X, Grignani G, Dumont S, Martinez-Trufero J, Palmerini E, Hindi N, Sebio A, Dopazo J, Dei Tos AP, LeCesne A, Blay JY, Cruz J.

Lancet Oncol. 2019 Jan;20(1):134-144. doi: 10.1016/S1470-2045(18)30676-4. Epub 2018 Dec 18.

PMID:
30578023
9.

Advancing towards Better Cooperation for Better Sarcoma Prognoses.

Martín Broto J.

Oncology. 2018;95 Suppl 1:5-10. doi: 10.1159/000494860. Epub 2018 Dec 14. Review.

10.

Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study.

Fucà G, Hindi N, Ray-Coquard I, Colia V, Dei Tos AP, Martin-Broto J, Brahmi M, Collini P, Lorusso D, Raspagliesi F, Pantaleo MA, Vincenzi B, Fumagalli E, Gronchi A, Casali PG, Sanfilippo R.

Oncologist. 2019 Jul;24(7):e536-e541. doi: 10.1634/theoncologist.2018-0338. Epub 2018 Dec 5.

PMID:
30518617
11.

Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS).

Martin-Broto J, Hindi N, Cruz J, Martinez-Trufero J, Valverde C, De Sande LM, Sala A, Bellido L, De Juan A, Rubió-Casadevall J, Diaz-Beveridge R, Cubedo R, Tendero O, Salinas D, Gracia I, Ramos R, Baguè S, Gutierrez A, Duran-Moreno J, Lopez-Pousa A.

Oncologist. 2019 Jun;24(6):e338-e346. doi: 10.1634/theoncologist.2018-0121. Epub 2018 Nov 8.

PMID:
30409793
12.

Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma.

Alemany R, Moura DS, Redondo A, Martinez-Trufero J, Calabuig S, Saus C, Obrador-Hevia A, Ramos R, Villar VH, Valverde C, Vaz MA, Medina J, Felipe-Abrio I, Hindi N, Taron M, Martin-Broto J.

Clin Cancer Res. 2018 Nov 1;24(21):5239-5249. doi: 10.1158/1078-0432.CCR-18-0851. Epub 2018 Jul 23.

13.

Options for treating different soft tissue sarcoma subtypes.

Ray-Coquard I, Serre D, Reichardt P, Martín-Broto J, Bauer S.

Future Oncol. 2018 May;14(10s):25-49. doi: 10.2217/fon-2018-0076. Review.

PMID:
29768052
14.

Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients.

Moura DS, Ramos R, Fernandez-Serra A, Serrano T, Cruz J, Alvarez-Alegret R, Ortiz-Duran R, Vicioso L, Gomez-Dorronsoro ML, Garcia Del Muro X, Martinez-Trufero J, Rubio-Casadevall J, Sevilla I, Lainez N, Gutierrez A, Serrano C, Lopez-Alvarez M, Hindi N, Taron M, López-Guerrero JA, Martin-Broto J.

Oncotarget. 2018 Apr 3;9(25):17576-17588. doi: 10.18632/oncotarget.24799. eCollection 2018 Apr 3.

15.

Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.

García Del Muro X, Maurel J, Martínez Trufero J, Lavernia J, López Pousa A, de Las Peñas R, Cubedo R, Berros JP, Casado Herráez A, de Juan A, Martín Broto J.

Invest New Drugs. 2018 Jun;36(3):468-475. doi: 10.1007/s10637-018-0583-z. Epub 2018 Mar 12.

PMID:
29527631
16.

High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial.

Pasquali S, Colombo C, Pizzamiglio S, Verderio P, Callegaro D, Stacchiotti S, Martin Broto J, Lopez-Pousa A, Ferrari S, Poveda A, De Paoli A, Quagliuolo V, Jurado JC, Comandone A, Grignani G, De Sanctis R, Palassini E, Llomboart-Bosch A, Dei Tos AP, Casali PG, Picci P, Gronchi A.

Eur J Cancer. 2018 Apr;93:28-36. doi: 10.1016/j.ejca.2018.01.071. Epub 2018 Feb 21.

PMID:
29475197
17.

Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study.

Martin-Liberal J, López-Pousa A, Martínez-Trufero J, Martín-Broto J, Cubedo R, Lavernia J, Redondo A, López-Martín JA, Mulet-Margalef N, Sanjuan X, Tirado ÒM, Garcia-Del-Muro X.

Target Oncol. 2018 Feb;13(1):81-87. doi: 10.1007/s11523-017-0539-9.

PMID:
29177953
18.

Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS).

Martin-Broto J, Redondo A, Valverde C, Vaz MA, Mora J, Garcia Del Muro X, Gutierrez A, Tous C, Carnero A, Marcilla D, Carranza A, Sancho P, Martinez-Trufero J, Diaz-Beveridge R, Cruz J, Encinas V, Taron M, Moura DS, Luna P, Hindi N, Lopez-Pousa A.

Ann Oncol. 2017 Dec 1;28(12):2994-2999. doi: 10.1093/annonc/mdx536.

PMID:
29045512
19.

Malignant bone tumors (other than Ewing's): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS).

Redondo A, Bagué S, Bernabeu D, Ortiz-Cruz E, Valverde C, Alvarez R, Martinez-Trufero J, Lopez-Martin JA, Correa R, Cruz J, Lopez-Pousa A, Santos A, García Del Muro X, Martin-Broto J.

Cancer Chemother Pharmacol. 2017 Dec;80(6):1113-1131. doi: 10.1007/s00280-017-3436-0. Epub 2017 Oct 16.

20.

Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib.

Joensuu H, Blay JY, Comandone A, Martin-Broto J, Fumagalli E, Grignani G, Del Muro XG, Adenis A, Valverde C, Pousa AL, Bouché O, Italiano A, Bauer S, Barone C, Weiss C, Crippa S, Camozzi M, Castellana R, Le Cesne A.

Br J Cancer. 2017 Oct 24;117(9):1278-1285. doi: 10.1038/bjc.2017.290. Epub 2017 Aug 29.

21.

GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS).

Mora J, Castañeda A, Perez-Jaume S, Lopez-Pousa A, Maradiegue E, Valverde C, Martin-Broto J, Garcia Del Muro X, Cruz O, Cruz J, Martinez-Trufero J, Maurel J, Vaz MA, de Alava E, de Torres C.

Br J Cancer. 2017 Sep 5;117(6):767-774. doi: 10.1038/bjc.2017.252. Epub 2017 Aug 8.

22.

Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.

Stacchiotti S, Mir O, Le Cesne A, Vincenzi B, Fedenko A, Maki RG, Somaiah N, Patel S, Brahmi M, Blay JY, Boye K, Sundby Hall K, Gelderblom H, Hindi N, Martin-Broto J, Kosela H, Rutkowski P, Italiano A, Duffaud F, Kobayashi E, Casali PG, Provenzano S, Kawai A.

Oncologist. 2018 Jan;23(1):62-70. doi: 10.1634/theoncologist.2017-0161. Epub 2017 Jul 28.

23.

Review of past and present clinical cases with a view to future treatment options.

Martín-Broto J, Reichardt P, Stacchiotti S, Blay JY.

Future Oncol. 2017 Jun;13(13s):11-28. doi: 10.2217/fon-2017-0120. Epub 2017 May 2. Review.

PMID:
28460536
24.

GEIS guidelines for gastrointestinal sarcomas (GIST).

Poveda A, García Del Muro X, López-Guerrero JA, Cubedo R, Martínez V, Romero I, Serrano C, Valverde C, Martín-Broto J; GEIS (Grupo Español de Investigación en Sarcomas/Spanish Group for Sarcoma Research).

Cancer Treat Rev. 2017 Apr;55:107-119. doi: 10.1016/j.ctrv.2016.11.011. Epub 2017 Mar 2. Review.

25.

Disruption of TCF/β-Catenin Binding Impairs Wnt Signaling and Induces Apoptosis in Soft Tissue Sarcoma Cells.

Martinez-Font E, Felipe-Abrio I, Calabuig-Fariñas S, Ramos R, Terrasa J, Vögler O, Alemany R, Martín-Broto J, Obrador-Hevia A.

Mol Cancer Ther. 2017 Jun;16(6):1166-1176. doi: 10.1158/1535-7163.MCT-16-0585. Epub 2017 Mar 14.

26.

[Early clinical trials in paediatric oncology in Spain: a nationwide perspective].

Bautista F, Gallego S, Cañete A, Mora J, Díaz de Heredia C, Cruz O, Fernández JM, Rives S, Berlanga P, Hladun R, Juan Ribelles A, Madero L, Ramírez M, Fernández Delgado R, Pérez-Martínez A, Mata C, Llort A, Martín Broto J, Cela ME, Ramírez G, Sábado C, Acha T, Astigarraga I, Sastre A, Muñoz A, Guibelalde M, Moreno L; en nombre de la Sociedad Española de Oncología Pediátrica (SEHOP) y el Grupo de Nuevas Terapias en Oncología Pediátrica; Sociedad Española de Hematología y Oncología Pediátrica (SEHOP) and the New Drug Development Group in Pediatric Oncology.

An Pediatr (Barc). 2017 Sep;87(3):155-163. doi: 10.1016/j.anpedi.2016.07.007. Epub 2017 Mar 6. Spanish.

27.

Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group.

Stacchiotti S, Gronchi A, Fossati P, Akiyama T, Alapetite C, Baumann M, Blay JY, Bolle S, Boriani S, Bruzzi P, Capanna R, Caraceni A, Casadei R, Colia V, Debus J, Delaney T, Desai A, Dileo P, Dijkstra S, Doglietto F, Flanagan A, Froelich S, Gardner PA, Gelderblom H, Gokaslan ZL, Haas R, Heery C, Hindi N, Hohenberger P, Hornicek F, Imai R, Jeys L, Jones RL, Kasper B, Kawai A, Krengli M, Leithner A, Logowska I, Martin Broto J, Mazzatenta D, Morosi C, Nicolai P, Norum OJ, Patel S, Penel N, Picci P, Pilotti S, Radaelli S, Ricchini F, Rutkowski P, Scheipl S, Sen C, Tamborini E, Thornton KA, Timmermann B, Torri V, Tunn PU, Uhl M, Yamada Y, Weber DC, Vanel D, Varga PP, Vleggeert-Lankamp CLA, Casali PG, Sommer J.

Ann Oncol. 2017 Jun 1;28(6):1230-1242. doi: 10.1093/annonc/mdx054. Review.

28.

Erratum to: Gastrointestinal stromal tumors (GISTs): SEAP-SEOM consensus on pathologic and molecular diagnosis.

Martin-Broto J, Martinez-Marín V, Serrano C, Hindi N, López-Guerrero JA, Biscuola M, Ramos-Asensio R, Vallejo-Benítez A, Marcilla-Plaza D, González-Cámpora R.

Clin Transl Oncol. 2017 May;19(5):650. doi: 10.1007/s12094-017-1619-0. No abstract available.

PMID:
28138952
29.

Gastrointestinal stromal tumors (GISTs): SEAP-SEOM consensus on pathologic and molecular diagnosis.

Martin-Broto J, Martinez-Marín V, Serrano C, Hindi N, López-Guerrero JA, Bisculoa M, Ramos-Asensio R, Vallejo-Benítez A, Marcilla-Plaza D, González-Cámpora R.

Clin Transl Oncol. 2017 May;19(5):536-545. doi: 10.1007/s12094-016-1581-2. Epub 2016 Dec 9. Erratum in: Clin Transl Oncol. 2017 May;19(5):650. Bisculoa M [added].

PMID:
27943096
30.

The importance of treating by histological subtype in advanced soft tissue sarcoma.

Martín Broto J, Le Cesne A, Reichardt P.

Future Oncol. 2017 Jan;13(1s):23-31. Review.

PMID:
27918201
31.

SEOM Clinical Guideline of management of soft-tissue sarcoma (2016).

López-Pousa A, Martin Broto J, Martinez Trufero J, Sevilla I, Valverde C, Alvarez R, Carrasco Alvarez JA, Cruz Jurado J, Hindi N, Garcia Del Muro X.

Clin Transl Oncol. 2016 Dec;18(12):1213-1220. doi: 10.1007/s12094-016-1574-1.

32.

SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016).

Poveda A, Martinez V, Serrano C, Sevilla I, Lecumberri MJ, de Beveridge RD, Estival A, Vicente D, Rubió J, Martin-Broto J.

Clin Transl Oncol. 2016 Dec;18(12):1221-1228. doi: 10.1007/s12094-016-1579-9. Epub 2016 Nov 28.

33.

Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.

Gronchi A, Stacchiotti S, Verderio P, Ferrari S, Martin Broto J, Lopez-Pousa A, Llombart-Bosch A, Dei Tos AP, Collini P, Jurado JC, De Paoli A, Donati DM, Poveda A, Quagliuolo V, Comandone A, Grignani G, Morosi C, Messina A, De Sanctis R, Bottelli S, Palassini E, Casali PG, Picci P.

Ann Oncol. 2016 Dec;27(12):2283-2288. doi: 10.1093/annonc/mdw430. Epub 2016 Oct 11.

PMID:
27733375
34.

Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1).

Perez M, Peinado-Serrano J, Garcia-Heredia JM, Felipe-Abrio I, Tous C, Ferrer I, Martin-Broto J, Saez C, Carnero A.

Oncotarget. 2016 Oct 11;7(41):67033-67046. doi: 10.18632/oncotarget.11475.

35.

Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study.

Maurel J, López-Pousa A, Calabuig S, Bagué S, Del Muro XG, Sanjuan X, Rubió-Casadevall J, Cuatrecasas M, Martinez-Trufero J, Horndler C, Fra J, Valverde C, Redondo A, Poveda A, Sevilla I, Lainez N, Rubini M, García-Albéniz X, Martín-Broto J, de Alava E.

Clin Sarcoma Res. 2016 Jun 29;6:10. doi: 10.1186/s13569-016-0050-6. eCollection 2016.

36.

Down-Regulation of AKT Signalling by Ursolic Acid Induces Intrinsic Apoptosis and Sensitization to Doxorubicin in Soft Tissue Sarcoma.

Villar VH, Vögler O, Barceló F, Martín-Broto J, Martínez-Serra J, Ruiz-Gutiérrez V, Alemany R.

PLoS One. 2016 May 24;11(5):e0155946. doi: 10.1371/journal.pone.0155946. eCollection 2016.

37.

Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study.

Martin-Broto J, Pousa AL, de Las Peñas R, García Del Muro X, Gutierrez A, Martinez-Trufero J, Cruz J, Alvarez R, Cubedo R, Redondo A, Maurel J, Carrasco JA, López-Martin JA, Sala Á, Meana JA, Ramos R, Martinez-Serra J, Lopez-Guerrero JA, Sevilla I, Balaña C, Vaz Á, De Juan A, Alemany R, Poveda A.

J Clin Oncol. 2016 Jul 1;34(19):2294-302. doi: 10.1200/JCO.2015.65.3329. Epub 2016 May 16.

PMID:
27185843
38.

Targeted treatments of sarcomas and connective tumors beside gastrointestinal stromal tumor.

Martin-Broto J, Hindi N.

Curr Opin Oncol. 2016 Jul;28(4):338-44. doi: 10.1097/CCO.0000000000000302. Review.

PMID:
27166665
39.

Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS).

Garcia del Muro X, de Alava E, Artigas V, Bague S, Braña A, Cubedo R, Cruz J, Mulet-Margalef N, Narvaez JA, Martinez Tirado O, Valverde C, Verges R, Viñals J, Martin-Broto J; Spanish Group for Research on Sarcoma.

Cancer Chemother Pharmacol. 2016 Jan;77(1):133-46. doi: 10.1007/s00280-015-2809-5. Epub 2015 Nov 12.

40.

Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas Randomized Clinical Trial: Three Versus Five Cycles of Full-Dose Epirubicin Plus Ifosfamide.

Palassini E, Ferrari S, Verderio P, De Paoli A, Martin Broto J, Quagliuolo V, Comandone A, Sangalli C, Palmerini E, Lopez-Pousa A, De Sanctis R, Bottelli S, Libertini M, Picci P, Casali PG, Gronchi A.

J Clin Oncol. 2015 Nov 1;33(31):3628-34. doi: 10.1200/JCO.2015.62.9394. Epub 2015 Sep 8.

PMID:
26351345
41.

RG7112, a small-molecule inhibitor of MDM2, enhances trabectedin response in soft tissue sarcomas.

Obrador-Hevia A, Martinez-Font E, Felipe-Abrio I, Calabuig-Fariñas S, Serra-Sitjar M, López-Guerrero JA, Ramos R, Alemany R, Martín-Broto J.

Cancer Invest. 2015;33(9):440-50. doi: 10.3109/07357907.2015.1064534. Epub 2015 Aug 17.

PMID:
26288114
42.

RG7112, a Small-Molecule Inhibitor of MDM2, Enhances Trabectedin Response in Soft Tissue Sarcomas.

Obrador-Hevia A, Martinez-Font E, Felipe-Abrio I, Calabuig-Fariñas S, Serra-Sitjar M, López-Guerrero JA, Ramos R, Alemany R, Martín-Broto J.

Cancer Invest. 2015 Aug 17. [Epub ahead of print]

PMID:
26279182
43.

Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion.

Maki RG, Blay JY, Demetri GD, Fletcher JA, Joensuu H, Martín-Broto J, Nishida T, Reichardt P, Schöffski P, Trent JC.

Oncologist. 2015 Jul;20(7):823-30. doi: 10.1634/theoncologist.2014-0471. Epub 2015 Jun 12. Review.

44.

Trabectedin clinical cases: use according to indication in diverse clinical scenarios.

Grignani G, Martín-Broto J, Schuler M, Reichardt P.

Future Oncol. 2015;11(11 Suppl):15-24. doi: 10.2217/fon.15.76.

PMID:
26043311
45.

Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery.

Joensuu H, Martin-Broto J, Nishida T, Reichardt P, Schöffski P, Maki RG.

Eur J Cancer. 2015 Aug;51(12):1611-7. doi: 10.1016/j.ejca.2015.05.009. Epub 2015 May 25. Review.

46.

Giant cell tumour of bone: new treatments in development.

López-Pousa A, Martín Broto J, Garrido T, Vázquez J.

Clin Transl Oncol. 2015 Jun;17(6):419-30. doi: 10.1007/s12094-014-1268-5. Epub 2015 Jan 24. Review.

47.

Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS).

Rubió-Casadevall J, Martinez-Trufero J, Garcia-Albeniz X, Calabuig S, Lopez-Pousa A, Del Muro JG, Fra J, Redondo A, Lainez N, Poveda A, Valverde C, De Juan A, Sevilla I, Casado A, Andres R, Cruz J, Martin-Broto J, Maurel J; Spanish Group for Research on Sarcoma (GEIS).

Ann Surg Oncol. 2015 Sep;22(9):2948-57. doi: 10.1245/s10434-014-4360-8. Epub 2015 Jan 22.

PMID:
25608769
48.

Indirect comparisons in cost-effectiveness analysis: are we being naïve?

Martin-Broto J.

Clin Transl Oncol. 2015 Jan;17(1):85-6. doi: 10.1007/s12094-014-1256-9. Epub 2014 Nov 21. No abstract available.

PMID:
25413140
49.

GEIS 2013 guidelines for gastrointestinal sarcomas (GIST).

Poveda A, del Muro XG, López-Guerrero JA, Martínez V, Romero I, Valverde C, Cubedo R, Martín-Broto J.

Cancer Chemother Pharmacol. 2014 Nov;74(5):883-98. doi: 10.1007/s00280-014-2547-0. Epub 2014 Sep 6. Review.

50.

Effects of denosumab on pain and analgesic use in giant cell tumor of bone: interim results from a phase II study.

Martin-Broto J, Cleeland CS, Glare PA, Engellau J, Skubitz KM, Blum RH, Ganjoo KN, Staddon A, Dominkus M, Feng A, Qian Y, Braun A, Jacobs I, Chung K, Atchison C.

Acta Oncol. 2014 Sep;53(9):1173-9. doi: 10.3109/0284186X.2014.910313. Epub 2014 May 19.

PMID:
24834795

Supplemental Content

Loading ...
Support Center